Aug. 29, 2014, 9:39 AM
- DelMar Pharmaceuticals (OTCQB:DMPI) six-month results: Revenues: $0; Operating Expenses: $2.7M (-27.5%); Net Loss: ($2.8M) (+80.3%); Loss Per Share: ($0.09) (+82.4%); Quick Assets: $4.8M (+15.1%); Cash Burn: ($1.8M) (+44.9%).
- On July 21, 2014 the BOD voted to change the fiscal year end from December 31 to June 30. The reported financial results are for the transition period.
- No financial guidance given.
DMPI vs. ETF Alternatives
Other News & PR